FDA Suggests Preoperational Review Meetings Before Submitting NDAs For Continuous Manufacturing
This article was originally published in The Gold Sheet
Executive Summary
FDA suggests early site visits before submitting NDAs and supplements for continuous manufacturing to smooth over rough patches before pre-approval inspections. Agency also shares some insights on what inspectors will be looking for during PAIs of continuous manufacturing facilities.
You may also be interested in...
Performance-Based Conditions Could Ease Post-Approval Changes For Process Analytical Technologies, Experts Say
Pharmaceutical industry officials are promoting the idea of “marrying” the concepts of performance-based approaches and process analytical technology in the draft ICH Q12 guideline. Embedding this idea in ICH Q12 would give industry more flexibility in managing post-approval changes and aligns with the guideline’s concept of lifecycle improvement.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.